Objective: To study the effect of Xiongshao capsule (XSC) on vascular remodeling in porcine coronary balloon injury model. Methods: Coronary artery restenosis model was established by oversized balloon injury at mid-r...Objective: To study the effect of Xiongshao capsule (XSC) on vascular remodeling in porcine coronary balloon injury model. Methods: Coronary artery restenosis model was established by oversized balloon injury at mid-region of the left anterior descending coronary artery. They were divided into 5 groups, untreated or treated with probucol, Xueguantong, low and high dose of XSC respectively, and compared. The effect of XSC on late lumen loss resulted from vascular remodeling was evaluated by quantitative histological method with combining histopathological analysis and coronary angiographic examination. Results: The (59±20)% of late lumen loss was caused by vascular remodeling and (41±20)% caused by intimal hyperplasia. Compared with the control group, all the treatment could significantly reduce the late lumen loss after balloon injury (P<0.05 or P<0.01), both low and high dose of XSC could significantly reduce the late lumen loss caused by remodeling (P<0.05 and P<0.01 respectively). Conclusion: Vascular remodeling plays an important role in late lumen stenosis formation in coronary artery after balloon injury. XSC could significantly inhibit the pathological vascular remodeling, and thus reduce the late lumen loss and prevent the restenosis of the injured coronary artery.展开更多
Objective: To evaluate the effect of Xiongshao Capsule (XS, 芎芍胶囊) in preventing clinical and angiographic restenosis after coronary angioplasty or/and stenting. Methods: The total of 108 coronary heart disease pat...Objective: To evaluate the effect of Xiongshao Capsule (XS, 芎芍胶囊) in preventing clinical and angiographic restenosis after coronary angioplasty or/and stenting. Methods: The total of 108 coronary heart disease patients with successful coronary angioplasty or/and stenting were randomly divided into the control group (55 cases, routine treatment) and the XS group (53 cases, routine treatment combined with XS). The recurrence of angina, clinical end-point events, changing of blood-stasis syndrome score (BSSS) and coronary angiography within 6 month after coronary angioplasty or/and stenting were observed. Results: Follow-up angiography was performed in 42 patients including 18 cases in the XS group (restenosis was observed in 7 patients) and 24 cases in the control group (restenosis was observed in 17 patients), there was significant difference between the occurrence of restenosis in XS and that in control group (P<0.05). The occurrence of clinical end-point events (death, nonfatal target lesion myocardial infarction, coronary artery bypass graft surgery, or repeat target-vessel angioplasty) in the XS group (18.8%) was significantly lower than that in the control group (40%)(P<0.05). The recurrent angina was observed in 13 cases in the XS group, there was significant difference as compared with 27 cases in the control group (P<0.05). There was also remarkable significance for the difference of base-line and follow-up BSSS between groups (P<0.01). Logistic multivariate stepwise regress analysis and multivariate regress analysis of the related factors with restenosis confirmed by coronary angiography showed that, the base-line BSSS and the difference of base-line and follow-up BSSS were important influencing factors on the occurrence of restenosis after interventional treatment (P<0.05). Conclusion: XS could markedly reduce the occurrence of angiographic restenosis, clinical end-point events and recurrent angina, improve condition of blood-stasis after coronary angioplasty or/and stenting. The severity of blood-stasis syndrome was an important influencing factor on the occurrence of restenosis. It still needs to be further demonstrated by large-scale, double-blinded, randomized and controlled study.展开更多
文摘Objective: To study the effect of Xiongshao capsule (XSC) on vascular remodeling in porcine coronary balloon injury model. Methods: Coronary artery restenosis model was established by oversized balloon injury at mid-region of the left anterior descending coronary artery. They were divided into 5 groups, untreated or treated with probucol, Xueguantong, low and high dose of XSC respectively, and compared. The effect of XSC on late lumen loss resulted from vascular remodeling was evaluated by quantitative histological method with combining histopathological analysis and coronary angiographic examination. Results: The (59±20)% of late lumen loss was caused by vascular remodeling and (41±20)% caused by intimal hyperplasia. Compared with the control group, all the treatment could significantly reduce the late lumen loss after balloon injury (P<0.05 or P<0.01), both low and high dose of XSC could significantly reduce the late lumen loss caused by remodeling (P<0.05 and P<0.01 respectively). Conclusion: Vascular remodeling plays an important role in late lumen stenosis formation in coronary artery after balloon injury. XSC could significantly inhibit the pathological vascular remodeling, and thus reduce the late lumen loss and prevent the restenosis of the injured coronary artery.
文摘Objective: To evaluate the effect of Xiongshao Capsule (XS, 芎芍胶囊) in preventing clinical and angiographic restenosis after coronary angioplasty or/and stenting. Methods: The total of 108 coronary heart disease patients with successful coronary angioplasty or/and stenting were randomly divided into the control group (55 cases, routine treatment) and the XS group (53 cases, routine treatment combined with XS). The recurrence of angina, clinical end-point events, changing of blood-stasis syndrome score (BSSS) and coronary angiography within 6 month after coronary angioplasty or/and stenting were observed. Results: Follow-up angiography was performed in 42 patients including 18 cases in the XS group (restenosis was observed in 7 patients) and 24 cases in the control group (restenosis was observed in 17 patients), there was significant difference between the occurrence of restenosis in XS and that in control group (P<0.05). The occurrence of clinical end-point events (death, nonfatal target lesion myocardial infarction, coronary artery bypass graft surgery, or repeat target-vessel angioplasty) in the XS group (18.8%) was significantly lower than that in the control group (40%)(P<0.05). The recurrent angina was observed in 13 cases in the XS group, there was significant difference as compared with 27 cases in the control group (P<0.05). There was also remarkable significance for the difference of base-line and follow-up BSSS between groups (P<0.01). Logistic multivariate stepwise regress analysis and multivariate regress analysis of the related factors with restenosis confirmed by coronary angiography showed that, the base-line BSSS and the difference of base-line and follow-up BSSS were important influencing factors on the occurrence of restenosis after interventional treatment (P<0.05). Conclusion: XS could markedly reduce the occurrence of angiographic restenosis, clinical end-point events and recurrent angina, improve condition of blood-stasis after coronary angioplasty or/and stenting. The severity of blood-stasis syndrome was an important influencing factor on the occurrence of restenosis. It still needs to be further demonstrated by large-scale, double-blinded, randomized and controlled study.
